Nanocis (Rhenium Sulfide)

Rhenium sulfide, the active ingredient in Nanocis, is a compound presented as an oral and subcutaneous formulation for investigational use. It is being studied for potential therapeutic effects in experimental settings. GNH USA supplies Nanocis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nanocis (rhenium sulfide) is currently under clinical investigation and has no approved therapeutic indications. - Investigational use: Evaluated in early‑phase studies for potential anti‑cancer activity. - Research applications: Utilized in laboratory models to explore metal‑dependent biochemical pathways. - Clinical trial enrollment: May be administered to participants under protocol‑defined conditions.

Adverse reactions reported for Nanocis are limited and primarily derived from early‑phase clinical observations.

Common Side Effects: - Mild gastrointestinal discomfort: occasional nausea or stomach upset. - Transient injection site irritation: redness or tenderness after subcutaneous administration. - Headache: occasional mild headache reported. - Laboratory abnormalities: occasional transient elevation of liver enzymes.

Serious or Rare Side Effects: - None reported: No serious adverse events have been documented in published studies. - Allergic reaction: rare hypersensitivity cases have been noted. - Severe hepatic dysfunction: not observed but would be monitored in future trials. - Anaphylaxis: no cases reported to date.

When handling Nanocis, consider the following safety measures: - Pregnancy: safety not established; avoid unless potential benefit justifies risk. - Breastfeeding: unknown; consider discontinuation during nursing. - Renal impairment: use with caution; monitor renal function. - Hepatic impairment: limited data; monitor liver enzymes. - Concomitant immunosuppressants: assess risk of additive immunomodulation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Potential drug interactions for Nanocis are based on its chemical properties and limited clinical data.

Major Interactions (Avoid): - Concurrent use with strong oxidizing agents: may alter compound stability.

Moderate Interactions (Monitor Closely): - Co‑administration with metal chelators: could reduce bioavailability. - Anticoagulants: observe for possible increased bleeding risk. - Antibiotics such as tetracyclines: potential binding may affect absorption. - Other investigational agents: monitor for additive toxicity.